These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 5043228)

  • 61. Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.
    Selawry OS
    Cancer Chemother Rep 3; 1973 Mar; 4(2):177-88. PubMed ID: 4277763
    [No Abstract]   [Full Text] [Related]  

  • 62. Palliative treatment of nonresectable lung cancer by upper hemibody perfusion of chlorimine (short-acting alkylating agent): experience with five cases.
    Sher MH; Trummer MJ; Moquin RB
    Am Surg; 1966 Jun; 32(6):385-7. PubMed ID: 4160225
    [No Abstract]   [Full Text] [Related]  

  • 63. Topical lomustine in the treatment of psoriasis.
    Peck GL; Guss SB; Key DJ
    Arch Dermatol; 1972 Aug; 106(2):172-6. PubMed ID: 4558698
    [No Abstract]   [Full Text] [Related]  

  • 64. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
    Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In vitro analysis of BCNU-sensitivity in human malignant gliomas. I. A model study with alkylating, cross-linking and carbamoylating agents in anaplastic astrocytomas of pediatric age.
    Gerosa MA; Rosenblum ML; Stevanoni G; Tommasi M; Della Corte V; Licata C; Bricolo A; Tridente G
    Acta Neurol Scand; 1985 Oct; 72(4):414-8. PubMed ID: 3002083
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 68. Interaction of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) with nucleic acids and proteins in vivo and in vitro.
    Cheng CJ; Fujimura S; Grunberger D; Weinstein IB
    Cancer Res; 1972 Jan; 32(1):22-7. PubMed ID: 5007685
    [No Abstract]   [Full Text] [Related]  

  • 69. Nephrotoxicity of streptozotocin (NSC-85998).
    Sadoff L
    Cancer Chemother Rep; 1970 Dec; 54(6):457-9. PubMed ID: 4334090
    [No Abstract]   [Full Text] [Related]  

  • 70. Treatment of resistant Hodgkin's disease.
    Lancet; 1971 Oct; 2(7729):860. PubMed ID: 4106882
    [No Abstract]   [Full Text] [Related]  

  • 71. Central nervous system leukemia and solid tumors of childhood. Treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU).
    Iriarte PV; Hananian J; Cortner JA
    Cancer; 1966 Sep; 19(9):1187-94. PubMed ID: 4288265
    [No Abstract]   [Full Text] [Related]  

  • 72. Patterns of intravenous glucose tolerance and insulin response before and after treatment with streptozotocin (NSC-85998) in patients with cancer.
    Sadoff L
    Cancer Chemother Rep; 1972 Feb; 56(1):61-9. PubMed ID: 4260577
    [No Abstract]   [Full Text] [Related]  

  • 73. The synthesis of potential anticancer agents. XXXVII. N-nitrosoureas. 3. 1,5-bis(2-chloroethyl)-1-nitrosobiuret and related derivatives of biurets, biureas, and carboxamides.
    Johnston TP; Opliger PS
    J Med Chem; 1967 Jul; 10(4):675-81. PubMed ID: 6037061
    [No Abstract]   [Full Text] [Related]  

  • 74. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug.
    Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
    Proc Natl Acad Sci U S A; 1970 Aug; 66(4):1089-95. PubMed ID: 5273445
    [TBL] [Abstract][Full Text] [Related]  

  • 75. 1,3-Bis (2-chloroethyl)-1-nitrosourea: effects on advanced ovarian carcinoma.
    Godfrey TE; King A; Rentschler R
    Am J Obstet Gynecol; 1973 Feb; 115(4):576-7. PubMed ID: 4685511
    [No Abstract]   [Full Text] [Related]  

  • 76. The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds.
    Montgomery JA; James R; McCaleb GS; Johnston TP
    J Med Chem; 1967 Jul; 10(4):668-74. PubMed ID: 6037060
    [No Abstract]   [Full Text] [Related]  

  • 77. Vinblastine sulfate (NSC-49842) in the treatment of bronchogenic carcinoma.
    Fink A; Finegold SM; Patno ME; Close HP; Whittington RM
    Cancer Chemother Rep; 1970 Dec; 54(6):451-2. PubMed ID: 4946013
    [No Abstract]   [Full Text] [Related]  

  • 78. Therapy of advanced gastrointestinal cancer with 1-3-bis-(2-chlorethyl)-1-nitrosourea (BCNU).
    Moertel CG; Reitemeier RJ; Hahn RG
    Clin Pharmacol Ther; 1968; 9(5):652-6. PubMed ID: 5676805
    [No Abstract]   [Full Text] [Related]  

  • 79. Quantitation of 1,3-bis(2-chloroethyl)-1-nitrosourea in plasma using high-performance liquid chromatography.
    Yeager RL; Oldfield EH; Chatterji DC
    J Chromatogr; 1984 Feb; 305(2):496-501. PubMed ID: 6423657
    [No Abstract]   [Full Text] [Related]  

  • 80. Colorimetric method for the determination of 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Loo TL; Dion RL
    J Pharm Sci; 1965 May; 54(5):809-10. PubMed ID: 5845903
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.